Newsfeeds - Spark Newswire

2 minute read

Acurx Highlights Nov. 5 Presentation Of New Microbiome Data From Its Phase 2a Clinical Trial Of Ibezapolstat At 9th International C. diff. Conference

Today, 1:06 PM

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial

ACXP

4 minute read

The Daily Biotech Pulse: NRx’s Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill

By Shanthi Rexaline

Today, 1:06 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ACXP

2 minute read

Acurx Pharma Reports Ibezapolstat Microbiome Data From Phase 2a Trial: ‘trial demonstrated 100% clinical cure and sustained clinical cure,’ Showed ‘Favorable microbiome changes included overgrowth’

By Benzinga Newsdesk

Today, 1:06 PM

- Patient fecal samples were evaluated for C. difficile culture and microbiome changes - Ph2a trial demonstrated 100% clinical cure and sustained clinical cure - Favorable microbiome changes included overgrowth of

ACXP

6 minute read

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline

By Shanthi Rexaline

Today, 1:06 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)

ABBV

20 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 1:06 PM

Tuesday morning, 282 companies set new 52-week lows.

AAOI

8 minute read

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business

By Shanthi Rexaline

Today, 1:06 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)

ABSI

1 minute read

Acurx Pharmaceuticals Q2 EPS $(0.57) Down From $(0.15) YoY

By Benzinga Newsdesk

Today, 1:06 PM

Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.57) per share. This is a 280 percent decrease over losses of $(0.15) per share from the same period last year.

ACXP